nelfinavir has been researched along with saquinavir in 277 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 63 (22.74) | 18.2507 |
| 2000's | 177 (63.90) | 29.6817 |
| 2010's | 33 (11.91) | 24.3611 |
| 2020's | 4 (1.44) | 2.80 |
| Authors | Studies |
|---|---|
| Fromm, MF; Kim, RB; Leake, B; Roden, DM; Wandel, C; Wilkinson, GR; Wood, AJ | 1 |
| Anderson, PS; Bacheler, LT; Chang, CH; Cordova, B; Erickson-Viitanen, S; Garber, S; Johnson, BL; Klabe, RM; Ko, SS; Lam, PY; Li, R; Reid, C; Rodgers, JD; Ru, Y; Seitz, SP; Trainor, GL; Wang, H; Wright, MR | 1 |
| Cvetkovic, M; Fromm, MF; Kim, RB; Leake, B; Wilkinson, GR | 1 |
| Abbenante, G; Fairlie, DP; Leung, D | 1 |
| Blaschke, TF; Giacomini, KM; Gorset, W; Kroetz, DL; Washington, CB; Zhang, L | 1 |
| Choo, EF; Imamura, H; Kim, RB; Leake, B; Wandel, C; Wilkinson, GR; Wood, AJ | 1 |
| Almond, MR; Bock, WJ; Cleary, DG; Furfine, ES; Hazen, RJ; Kazmierski, WM; Salituro, FG; Spaltenstein, A; Tung, RD; Wright, LL | 1 |
| Daily, JP; Fahey, JM; Greenblatt, DJ; Perloff, MD; von Moltke, LL | 1 |
| Chen, IW; Darke, PL; Dorsey, BD; Emini, EA; Hoffman, JM; Holloway, MK; Huff, JR; Kuo, LC; Levin, RB; Lin, JH; McDaniel, SL; McDonough, C; Michelson, SR; Newton, CL; Olsen, DB; Rutkowski, CA; Schleif, WA; Stahlhut, MW; Vacca, JP; Zugay-Murphy, JA | 1 |
| Classon, B; Hallberg, A; Kvarnström, I; Lindberg, J; Pyring, D; Samuelsson, B; Unge, T; Vrang, L; Zhang, H; Zuccarello, G | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Gorey-Feret, LJ; Murphy, PV; O'Brien, JL; Smith, AB | 1 |
| Danielson, UH; Hallberg, A; Hämäläinen, M; Karlén, A; Markgren, PO; Samuelsson, B; Schaal, W | 1 |
| Kim, RB; Leake, BF; Tirona, RG; Wolkoff, AW | 1 |
| Freire, E; Muzammil, S; Ross, P | 1 |
| Fischer, H; Huwyler, J; Poli, S; Schwab, D; Tabatabaei, A | 1 |
| Gupta, A; Mao, Q; Unadkat, JD; Zhang, Y | 1 |
| Danielson, UH; Shuman, CF; Vrang, L | 1 |
| Azijn, H; de Bethune, MP; de Kock, HA; De Meyer, S; King, NM; Maes, LJ; Pauwels, R; Peeters, A; Pille, GM; Prabu-Jeyabalan, M; Schiffer, CA; Surleraux, DL; Vendeville, S; Verschueren, WG; Wigerinck, PB | 1 |
| Bertucci, C; Cimitan, S; Danielson, UH; Lindgren, MT | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Andrews, CW; Brieger, M; Furfine, ES; Hale, MR; Hanlon, MH; Hazen, RJ; Kaldor, I; McLean, EW; Miller, JF; Reynolds, D; Sammond, DM; Sherrill, RG; Spaltenstein, A; Tung, R; Turner, EM; Xu, RX | 1 |
| Agbandje-McKenna, M; Clemente, JC; Coman, RM; Dunn, BM; Goodenow, MM; Govindasamy, L; Janka, LK; Jeung, JA; Leelamanit, W; McKenna, R; Nukoolkarn, S; Thiaville, MM | 1 |
| Das, D; Gatanaga, H; Ghosh, AK; Grum-Tokars, V; Hussain, AK; Koh, Y; Kovalevsky, AY; Leshchenko, S; Li, J; Maeda, K; Mitsuya, H; Sridhar, PR; Walters, DE; Weber, IT; Wedekind, JE | 1 |
| Dekhtyar, T; Kempf, DJ; Lu, L; Mo, H; Molla, A; Parkin, N; Stewart, KD | 1 |
| Amano, M; Boross, PI; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Li, J; Mitsuya, H; Wang, YF; Weber, IT | 1 |
| Bernstein, B; Dekhtyar, T; Gao, F; Hanna, GJ; Kempf, D; Koev, G; Lu, L; Lu, X; Masse, S; Mo, H; Molla, A | 1 |
| Dandache, S; Parkin, N; Schapiro, JM; Sévigny, G; Stranix, BR; Wainberg, MA; Wu, JJ; Yelle, J | 1 |
| Babusis, D; Bhoopathy, S; Hidalgo, IJ; Phan, TK; Ray, AS; Rhodes, GR; Robinson, KL; Strab, R; Tong, L | 1 |
| Aubertin, AM; Greiner, J; Roche, D; Vierling, P | 1 |
| Hayashi, H; Mimoto, T; Nojima, S; Shintani, M; Takaku, H; Terashima, K | 1 |
| DeGoey, DA; Dekhtyar, T; Flosi, WJ; Grampovnik, DJ; Kempf, DJ; Klein, LL; Lu, L; Masse, S; Molla, A; Ng, TI | 1 |
| Bénard, A; Brun-Vézinet, F; Campa, P; Chêne, G; Collin, G; Damond, F; Desbois, D; Descamps, D; Matheron, S; Peytavin, G; Roquebert, B | 1 |
| Chen, L; Chen, X; He, Z; Peng, N; Qin, L; You, J | 1 |
| Brynda, J; Cígler, P; Fanfrlík, J; Grantz Sasková, K; Grüner, B; Konvalinka, J; Kozísek, M; Král, V; Lepsík, M; Plesek, J; Pokorná, J; Rezácová, P; Václavíková, J | 1 |
| Amano, M; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Mitsuya, H; Nakata, H; Nakayama, M; Ogata-Aoki, H | 1 |
| Antonsson, M; Bengtsson, O; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Jerndal, G; Wan, H; Winiwarter, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Berti, F; Bonini, C; Chiummiento, L; De Bonis, M; Di Blasio, N; Funicello, M; Lupattelli, P; Pandolfo, R; Tramutola, F | 1 |
| Amano, M; Anderson, DD; Aoki, M; Das, D; Ghosh, AK; Koh, Y; Kulkarni, S; Mitsuya, H; Tojo, Y | 1 |
| Kempf, DJ; Norton, M; Parkin, NT; Pilot-Matias, T; Stawiski, E; Trinh, R; Young, TP | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
| Cane, PA; Kolli, M; Myers, RE; Parry, CM; Pillay, D; Schiffer, C | 1 |
| Ballard, TE; Henderson, JL; Kalgutkar, AS; Obach, RS; Orr, ST; Ripp, SL; Scott, DO; Sun, H | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Carmen Villaverde, M; Domínguez, JL; Gossas, T; Helena Danielson, U; Sussman, F | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Diederich, WE; Kuhnert, M; Steuber, H | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Esaki, T; Kawashima, H; Komura, H; Kuroda, M; Mizuguchi, K; Natsume-Kitatani, Y; Ohashi, R; Watanabe, R | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Blair, ED; Darby, G; Furfine, ES; Maschera, B; Myers, R; Palú, G; Tisdale, M; Wright, LL | 1 |
| Deeks, SG; Holodniy, M; Kahn, JO; Smith, M | 1 |
| Kuritzkes, DR; McDonald, CK | 1 |
| Ferrando, S; Rabkin, JG | 1 |
| Back, DJ; Barry, MG; Halifax, KL; Merry, C; Mulcahy, F | 1 |
| Grodesky, MJ; Klaus, BD | 1 |
| Chiba, N; Hayashi, H; Shintani, M; Ueno, T | 1 |
| Burton, S; Carr, A; Chisholm, DJ; Cooper, DA; Freund, J; Law, M; Samaras, K | 1 |
| Beijnen, JH; de Wolf, F; Frissen, PH; Hoetelmans, RM; Jurriaans, S; Lange, JM; Mulder, JW; Reijers, MH; Roos, M; Schuitemaker, H; ten Kate, RW; Weigel, HM; Weverling, GJ; Wit, FW | 1 |
| Cammack, N; Chirn, GW; Craig, C; Dissanayeke, S; Duncan, IB; Gilbert, S; Moffatt, A; Race, E; Rose, J; Sheldon, J; Whittaker, L | 1 |
| Saag, MS; Schooley, RT | 1 |
| Boden, D; Markowitz, M | 1 |
| Blaschke, TF; Duran, GE; Man, MC; Sikic, BI; Washington, CB | 1 |
| Chronister, CL; Gurwood, AS | 1 |
| Brew, BJ; Markus, R | 1 |
| Lien, EJ; Ren, S | 1 |
| Holtzer, CD; Varav, H | 1 |
| Bruisten, SM; de Wolf, F; Frissen, PH; Jurriaans, S; Lange, JM; Mulder, JW; Reijers, MH; Schuitemaker, H; ten Kate, RW; van Leeuwen, R; Weigel, HM; Weverling, GJ; Wit, FW | 1 |
| Diehl, V; Fätkenheuer, G; Hoetelmans, R; Reiser, M; Salzberger, B; Stiepel, A | 1 |
| Kuper, JJ; Malaty, LI | 1 |
| D'Aquila, RT; Martinez-Picado, J; Savara, AV; Sutton, L | 1 |
| Erice, A; Henry, K; Kane, EM; Klebert, MK; Patick, AK; Powderly, WG; Simpson, JH; Tebas, P | 1 |
| Ceballos, J; Iglesias, M; Ostrosky-Zeichner, L; Ponce-de-Leon, S | 1 |
| Carver, PL; Cinti, SK; Kaul, DR; Kazanjian, PH | 1 |
| Dubreuil, L; Gérard, Y; Maulin, L; Mouton, Y | 1 |
| Efron, B; Lawrence, J; Merigan, TC; Montoya, J; Pesano, R; Schapiro, J; Winslow, D; Winters, M; Zolopa, A | 1 |
| Becker, M; Chesney, M; Deeks, SG; Grant, RM; Hellmann, NS; Parkin, NT; Petropoulos, CJ; Symonds, W; Volberding, PA | 1 |
| Burger, DM; Hekster, YA; Hugen, PW; Koopmans, PP; Verweij-van Wissen, CP; Wuis, EW | 1 |
| Brendel, V; Craig, C; Hsu, P; Patick, AK; Shafer, RW | 1 |
| Angel, JB; Ashby, D; Badley, AD; Cameron, DW; Kravcik, S; Kumar, A; Lynch, DH; Parato, K; Phenix, BN; Tschopp, J | 1 |
| Barnett, SH; Gallant, JE; Hall, CS; Moore, RD; Raines, CP | 1 |
| Altfeld, M; Fätkenheuer, G; Kaiser, R; Kupfer, B; Rockstroh, JK; Salzberger, B; Schneweis, KE; Spengler, U | 1 |
| Fitzgibbon, JE; Hua, J; Liao, MJ; Moussazadeh, M; Rashidbaigi, A; Sidhu, MK; Zhao, XX | 1 |
| Cheseaux, JJ; Darioli, R; Glauser, MP; Halfon, P; Marcovina, SM; Mooser, V; Nicod, P; Périard, D; Reymond, MJ; Sudre, P; Telenti, A | 1 |
| Kessler, CM; Racoosin, JA | 1 |
| Heald, AE; Heffron, S; Schiffman, SS; Zervakis, J | 1 |
| Back, DJ; Eagling, VA; Profit, L | 1 |
| Angel, JB; Badley, AD; Cameron, DW; Garber, GE; Kravcik, S; Victor, G | 1 |
| Brooks, D; DiMassimo, E; Dusek, A; Eron, JJ; Gleavy, J; Hopkins, S; Ngo, L; Pilcher, CD; Sista, P; Venetta, T | 1 |
| Abumi, H; Ajisawa, A; Fukutake, K; Gouchi, K; Hanabusa, H; Higasa, S; Ishikawa, M; Iwamoto, A; Kakishita, E; Kashiwagi, S; Koike, M; Matsuda, M; Mimaya, J; Miura, T; Nagai, Y; Oishi, T; Okano, A; Shirahata, A; Sugiura, W; Takamatsu, J; Takata, N; Taki, M; Yamada, K | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Matsumura, Y; Takada, K; Yamaji, H; Yoshikawa, Y | 1 |
| Fletcher, CV; Kawle, SP; Remmel, RP; Weller, D | 1 |
| George, SL; Knudson, R; Stapleton, JT; Swindells, S | 1 |
| Bendfeldt, K; Bode, H; Fromm, M; Riecken, EO; Schmidt, W; Schulzke, JD; Ullrich, R; Wahnschaffe, U; Zippel, T | 1 |
| Belohradsky, BH; Eberle, J; Gürtler, L; Hoffmann, F; Notheis, G; Wintergerst, U | 1 |
| Danielson, UH; Hämäläinen, M; Markgren, PO | 1 |
| Anderson, C; Craik, CS; Jolly, DJ; Todd, S | 1 |
| Heinrikson, RL; Tomasselli, AG | 1 |
| Hart, AA; Hoetelmans, RM; Lange, JM; Mulder, JW; Reijers, MH; Reiss, P; Schuitemaker, H; Ten Kate, RW; Weigel, HM; Weverling, GJ | 1 |
| Klinker, H; Langmann, P; Richter, E; Schlör, C; Väth, T; Weissbrich, B; Zilly, M | 1 |
| Bart, PA; Chapuis, A; De Boer, RJ; Fox, CH; Halkic, N; Hoover, S; Lange, JM; Lazzarin, A; Miller, V; Notermans, DW; Pantaleo, G; Perrin, L; Rizzardi, GP; Staszewski, S; Tambussi, G | 1 |
| Clumeck, N; DelFraissy, JF; DeLora, P; Duff, F; Johnson, M; Moyle, G; Opravil, M; Pelgrom, J; Pozniak, A; Reynes, J; Salgo, M; Vittecoq, D | 1 |
| Granda, BW; Greenblatt, DJ; Harmatz, JS; Shader, RI; von Moltke, LL; Zalma, A | 1 |
| Delfraissy, JF; Frau, E; Furlan, V; Goujard, C; Labetoulle, M; Lantz, O; Lecointe, D; Niessen, F; Offret, H; Rogier, H | 1 |
| Butler, KM; Clarke, SM; Condon, S; Healy, CM; Mulcahy, F | 1 |
| Angel, JB; Badley, AD; Cameron, DW; Cassol, S; Chambers, KA; Gallicano, K; Hawley-Foss, N; Kravcik, S; Mandy, F; Parato, K; Phenix, BN | 1 |
| Biollaz, J; Buclin, T; Decosterd, LA; Marzolini, C; Telenti, A | 1 |
| Chapuis, A; Corpataux, JM; Fleury, S; Knabenhans, C; Lazzarin, A; Meuwly, JY; Miedema, F; Pantaleo, G; Rizzardi, GP; Simeoni, E; Tambussi, G | 1 |
| Allende, MC; Belloso, WH; Benetucci, JA; Cahn, PE; Davey, RT; Emery, S; Lane, HC; Lasala, MC; Law, MG; Lopardo, G; Losso, MH; Nelson, E; Salomon, H; Saracco, M | 1 |
| Agostoni, F; Angeli, E; Atzori, C; Cargnel, A; Mainini, A; Micheli, V | 1 |
| Alessi, F; Bonfanti, P; Carradori, S; Di Cintio, E; Faggion, I; Fortuna, P; Gabbuti, A; Ghiselli, G; Landonio, S; Martinelli, C; Parazzini, F; Pusterla, L; Quirino, T; Timillero, L; Valsecchi, L | 1 |
| Decker, CF; Martin, GJ; Smith, JH | 1 |
| Abeli, C; Adorni, F; Bini, T; Bongiovanni, M; Castelnuovo, B; Chiesa, E; d'Arminio Monforte, A; Melzi, S; Sollima, S; Testa, L | 1 |
| Jaillon, P; Poirier, JM; Radembino, N; Robidou, P | 1 |
| Condra, JH; Emini, EA; Petropoulos, CJ; Schleif, WA; Shivaprakash, M; Ziermann, R | 1 |
| Croom, DK; Furfine, ES; Lenhard, JM; Reynolds, DJ; Spaltenstein, A; Weiel, JE | 1 |
| Biryahwaho, B; Dondero, T; Downing, R; Hu, DJ; Lal, R; Mastro, T; Nkengasong, J; Pieniazek, D; Rayfield, M; Soriano, V; Tanuri, A; Wiktor, SZ | 1 |
| Ammassari, A; Baldini, F; Cingolani, A; De Luca, A; Di Giambenedetto, S; Murri, R | 1 |
| Blanchard, SG; Furfine, ES; Ittoop, O; Jain, RG; Lenhard, JM; Orband-Miller, LA; Paulik, MA; Weiel, JE | 1 |
| D'Aquila, RT; Martinez-Picado, J; Savara, AV; Shi, L; Sutton, L | 1 |
| Freire, E; Luque, I; Todd, MJ; Velázquez-Campoy, A | 1 |
| Acosta, E; Cheng, H; Fischl, M; Fiscus, SA; Fletcher, CV; Freimuth, W; Gulick, RM; Haubrich, R; Hu, XJ; Katzenstein, D; Lagakos, SW; Mills, C; Pettinelli, C; Snyder, S; Swanstrom, R | 1 |
| Tavel, JA | 1 |
| Bart, PA; Chapuis, AG; Lazzarin, A; Pantaleo, G; Rizzardi, GP; Tambussi, G | 1 |
| Kawaguchi, Y; Matsumura, Y; Ohtani, A; Okamoto, H; Shibata, N; Takada, K; Yoshikawa, Y | 1 |
| Acosta, EP; Cheng, H; Fischl, M; Fletcher, CV; Gulick, RM; Haubrich, R; Hu, XJ; Katzenstein, D; Mills, C; Raasch, R; Remmel, RP | 1 |
| Croom, DK; Lenhard, JM; Weiel, JE; Winegar, DA | 1 |
| Barreiro, P; Gonzalez-Lahoz, J; Soriano, V | 1 |
| Airoldi, M; Carosi, G; Castelli, F; Patroni, A; Quiros-Roldan, E; Signorini, S; Torti, C | 1 |
| Antela, A; Casado, JL; Dehertogh, P; Dronda, F; Hertogs, K; Martí-Belda, P; Moreno, S; Sabido, R | 1 |
| Hoetelmans, RM; Jurriaans, S; Lange, JM; Mulder, JW; Reijers, MH; Richter, C; Roos, MT; Schuitemaker, H; Sprenger, H; Ten Kate, RW; Ter Hofstede, HJ; Weigel, HM; Weverling, GJ; Wit, FW | 1 |
| Bode, H; Fromm, M; Riecken, EO; Schmidt, W; Schulzke, JD; Ullrich, R | 1 |
| Bouley, M; Briere, C; Padoin, C; Petitjean, O; Tod, M | 1 |
| Gatell, J; Lazzarin, A; Lundgren, JD; Miller, V; Mocroft, A; Parkin, JM; Phillips, AN; Roge, B; van Lunzen, J; Weber, R | 1 |
| Koranyi, KI; Nahata, MC; Temple, ME | 1 |
| Kravcik, S | 1 |
| Freire, E; Todd, MJ; Vega, S; Velazquez-Campoy, A | 1 |
| Levin, J | 1 |
| Smart, T | 1 |
| Mascolini, M | 1 |
| Gomez, E | 1 |
| Back, DJ; Davey, R; Hoggard, PG; Jones, K; Khoo, S; Sales, SD | 1 |
| Abell, AD; Edmonds, MK | 1 |
| Iwamoto, A; Kotaki, H; Nakamura, T; Yamada, H | 1 |
| Danielson, UH; Gertow, K; Hämäläinen, M; Karlsson, R; Lindgren, MT; Markgren, PO | 1 |
| Blanco, JL; Carné, X; Gatell, JM; López-Púa, Y; Mallolas, J; Sarasa-Nacenta, M | 1 |
| Mitchell, SM; Newson, RB; Zambarakji, HJ | 1 |
| Beall, GN; Chang, ES; Liu, YT; Tetreault, DD | 1 |
| Arrizabalaga, J; Clotet, B; Martínez-Picado, J; Ruiz, L | 1 |
| Brundage, RC; Buss, NE; Calles, NR; Craig, C; DeLora, P; Duff, F; Eason, M; Fletcher, CV; Jorga, K; Kline, MW; Schwarzwald, H; Snell, P | 1 |
| Cauda, R; Leone, G; Lucia, MB; Rutella, S; Vella, S | 1 |
| Bartoli, A; Feroggio, M; Gianelli, L; Maserati, R; Montagna, M; Regazzi, MB; Villani, P | 1 |
| Bourin, M; Dailly, E; Jolliet, P; Kergueris, MF; Thomas, L | 1 |
| Badley, AD; Lum, JJ; Nie, Z; Phenix, BN; Sanchez-Dardon, J | 1 |
| Back, DJ; Bray, PG; Davey, RA; Jones, K; Khoo, SH; Meaden, ER; Ward, SA | 1 |
| Burger, DM; Chesney, MA; Danner, SA; de Wolf, F; Hoetelmans, RM; Hugen, PW; Jambroes, M; Kauffmann, RH; Lange, JM; Meenhorst, PL; Nieuwkerk, PT; Schneider, MM; Schrey, G; Sprangers, MA; Sprenger, HG; van Der Ende, ME | 1 |
| Gantke, B; Kuschak, D; Mauss, S; Schmutz, G | 1 |
| Borleffs, JC; Boucher, CA; Reedijk, M; Richter, C; Wensing, AM | 1 |
| Aubertin, AM; Gaucher, B; Greiner, J; Guedj, R; Rouquayrol, M; Vierling, P | 1 |
| Eron, JJ; Gillotin, C; Haubrich, R; Lang, W; Lou, Y; Sadler, BM; Stein, DS | 1 |
| Pereira, A; Taylor, S | 1 |
| Antela, A; Casado, JL; Dehertogh, P; Dronda, F; Hertogs, K; Moreno, A; Moreno, S; Perez-Elías, MJ | 1 |
| Barbour, JD; Deeks, SG; Grant, RM; Martin, JN | 1 |
| Back, DJ; Eagling, VA; Whitcombe, IW; Wiltshire, H | 1 |
| Gao, W; Kishida, T; Okamoto, H; Shibata, N; Takada, K; Yoshikawa, Y | 1 |
| Jaillon, P; Poirier, JM; Robidou, P | 2 |
| de Groot, R; Fraaij, PL; van Rossum, AM | 1 |
| Brundage, RC; Calles, NR; Delora, P; Duff, F; Fletcher, CV; Grub, S; Jorga, K; Kline, MW; Lüdin, E; Schwarzwald, H | 1 |
| Jain, RG; Lenhard, JM | 1 |
| Piliero, PJ | 1 |
| Goodsell, DS; Morris, GM; Olson, AJ; Sanner, MF; Stoffler, D | 1 |
| Edno-Mcheik, L; Lagrange, F; Molimard, M; Moore, N; Péhourcq, F; Titier, K | 1 |
| Choo, PW; Colson, AE; Keller, MJ; Pettus, PT; Platt, R; Sax, PE | 1 |
| Freire, E; Vega, S; Velazquez-Campoy, A | 1 |
| Aberg, JA; Bennett, KK; Bessen, LJ; Brosgart, C; DeGruttola, V; Eron, JJ; Gulick, RM; Hammer, SM; Holohan, MK; Karol, CN; Lewis, RH; Mellors, JW; Mitsuyasu, RT; Rogers, MD; Saah, AJ; Sheiner, L; Vaida, F; Valentine, FT; Wheat, LJ | 1 |
| Gao, W; Kageyama, M; Kimura, K; Kishida, T; Shibata, N; Takada, K; Yoshikawa, Y | 1 |
| Bennett, KK; Hammer, SM; Labbé, L; Lu, JF; Mellors, J; Pfister, M; Rosenkranz, S; Sheiner, LB | 1 |
| Grub, S; Jorga, K; Kline, MW; Schwarzwald, HL | 1 |
| Aweeka, FT; Chi, J; Jayewardene, AL; Motoya, T; Stone, JA | 1 |
| Aulagner, G; Bleyzac, N; Bourhis, Y; Coudray, S; Favetta, P; Gagneu, MC; Janoly, A; Oger, I | 1 |
| Carr, A; Chisholm, DJ; Cooper, DA; Gan, SK; Kraegen, EW; Samaras, K; Thompson, CH | 1 |
| Blaschke, TF; Flexner, C; Lu, JF; Rosenkranz, SL; Sheiner, LB | 1 |
| Gaucher, B; Greiner, J; Roche, D; Rouquayrol, M; Vierling, P | 1 |
| Justesen, US; Pedersen, C | 1 |
| Bashan, N; Ben-Romano, R; Klip, A; Riesenberg, K; Rudich, A; Schlaeffer, F; Török, D; Vanounou, S | 1 |
| Fukumoto, K; Fukushima, K; Gao, W; Inoue, Y; Kageyama, M; Nishimura, A; Shibata, N; Tadano, J; Takada, K; Yamasaki, D; Yoshikawa, Y | 1 |
| Brodt, HR; Findhammer, S; Helm, EB; Nolte, B; Wolf, T | 1 |
| Bratt, G; Ståhle, L | 1 |
| Feinberg, J; Goodrich, J; Greenberg, RN; Pilson, RS; Siemon-Hryczyk, P | 1 |
| Aberg, JA; Blaschke, TF; Flexner, C; Rosenkranz, SL; Segal, Y; Sheiner, LB; Washington, CB | 1 |
| DiFrancesco, R; Frerichs, VA; Keil, K; Morse, G | 1 |
| Burger, DM; Droste, JA; Verweij-Van Wissen, CP | 1 |
| Bartlett, JG; Celentano, DD; Lai, H; Lai, S; Lima, JA; Margolick, J; Ren, S; Vlahov, D | 1 |
| Gerstoft, J; Katzenstein, TL; Kirk, O; Lundgren, JD; Mathiesen, L; Nielsen, H; Obel, N; Pedersen, C | 1 |
| Brady, M; Cox, S; Crim, L; Gerber, N; Koranyi, K; Utkin, I; Walson, PD | 2 |
| Ailhaud, G; Azoulay, S; Dani, C; Duval, D; Guedj, R; Vernochet, C | 1 |
| Aubertin, AM; Gaucher, B; Greiner, J; Roche, D; Rouquayrol, M; Vierling, P | 1 |
| Gerstoft, J; Katzenstein, TL; Kirk, O; Lundgren, JD; Mathiesen, LR; Nielsen, H; Obel, N; Pedersen, C | 1 |
| Acosta, EP; Brundage, RC; Fletcher, CV; Gulick, RM; Haubrich, R; Jiang, H; Katzenstein, D | 1 |
| Das, S; Schray, KJ; Sipos, T; Stewart, RP; Wignot, TM | 1 |
| DeGoey, DA; Randolph, JT | 1 |
| Chappuy, H; Dimet, J; Firtion, G; Fouché, M; Mandelbrot, L; Pons, G; Rey, E; Tréluyer, JM | 1 |
| Chaisson, RE; Mehta, SH; Moore, RD; Sulkowski, MS; Thomas, DL | 1 |
| Klein, HH; Meier, M; Schütt, M; Zhou, J | 1 |
| Gerber, JG; Wyles, DL | 1 |
| Anselmino, A; Buccinnà, B; Dematteis, A; Mostert, M; Palmisano, L; Piccinini, M; Ramondetti, C; Ricotti, E; Rinaudo, MT; Tovo, PA | 1 |
| Chai, H; Chen, C; Li, M; Lin, PH; Lumsden, AB; Yan, S; Yang, H; Yao, Q | 1 |
| Badley, A; Castedo, M; Kroemer, G; Métivier, D; Paulau, AL; Perfettini, JL; Rizzuto, R; Roumier, T; Simoni, AM; Szabadkai, G | 1 |
| Bendfeldt, K; Bode, H; Fromm, M; Kraemer, OH; Kroesen, AJ; Lenzner, L; Schulzke, JD; Stoltenburg-Didinger, G; Ullrich, R; Zeitz, M | 1 |
| Boix, V; Garcia-Henarejos, JA; Gimeno, A; Llopis, C; Martínez-Madrid, O; Merino, E; Portilla, J; Sánchez-Paya, J | 1 |
| Backman, JT; Granfors, MT; Kajosaari, LI; Laitila, J; Neuvonen, PJ; Wang, JS | 1 |
| Fuchs, D; Gisslén, M; Hagberg, L; Nillroth, U; Ståhle, L; Svensson, JO; Yilmaz, A | 1 |
| Bacheler, L; Corral, A; de Mendoza, C; Pattery, T; Soriano, V; Valer, L | 1 |
| Fuse, T; Kitazato, K; Kobayashi, N; Watanabe, K | 1 |
| Harris, M; Hogg, RS; Montaner, JS; Moore, DM; Wood, E; Yip, B | 1 |
| Alviano, CS; dos Santos, AL; Kneipp, LF; Palmeira, VF | 1 |
| de Hoon, J; Van Wijngaerden, E; Verbesselt, R | 1 |
| Balfour, HH; Brundage, RC; Vezina, HE; Weller, DR | 1 |
| Ariyoshi, K; Bouzas, MB; Brigido, LF; Cahn, P; Camacho, R; Cane, P; Carvalho, AP; Clarke, J; Deforche, K; Grossman, Z; Harrigan, PR; Holguin, A; Kantor, R; Katzenstein, DA; Moreau, Y; Morris, L; Phanuphak, P; Pillay, D; Rodrigues, R; Rudich, H; Shafer, RW; Shapiro, JM; Silander, T; Sirivichayakul, S; Snoeck, J; Soares, MA; Soriano, V; Sugiura, W; Tanuri, A; Van Laethem, K; Vandamme, AM; Weber, J; Wynhoven, B | 1 |
| Atzori, C; Cargnel, A; Maruzzi, M; Mazza, F; Regazzi, M; Tronconi, E; Valerio, A; Villani, P | 1 |
| Choi, SO; Kashuba, AD; Rezk, NL | 1 |
| Arastéh, K; Becker, M; Berger, M; Breske, A; Herzmann, C; Hill, A; Kruse, G; Kurowski, M; Schulbin, H; Steinmüller, J; Stocker, H | 1 |
| Chew, N; Cotter, E; Doran, PP; Malizia, AP; Powderly, WG | 1 |
| Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R | 1 |
| Chao, Y; Grigorian, A; Hurford, R; Langford, TD; Patrick, C | 1 |
| Houston, JB; Parker, AJ | 1 |
| Cheung, C; Gonzalez, FJ; Idle, JR; Krausz, KW; Ma, X; Shah, YM; Wang, T | 1 |
| Garg, R; Messier, N; Ouellette, M; Sundar, S; Tremblay, MJ; Trudel, N | 1 |
| Alviano, CS; Kneipp, LF; Palmeira, VF; Rozental, S; Santos, AL | 1 |
| Louis, JM; Sayer, JM | 1 |
| Boesmans, D; Di Fazio, V; Elens, L; Haufroid, V; Vanbinst, R; Veriter, S; Wallemacq, P | 1 |
| Chow, WA; Guan, M; Jiang, C | 1 |
| Abecasis, AB; Camacho, RJ; Santos, AF; Soares, MA; Vandamme, AM | 1 |
| Agrawal, KC; Chandra, S; Mondal, D | 1 |
| Elmquist, WF; Giri, N; Shaik, N | 1 |
| Burgers, PC; Dekker, LJ; Gruters, RA; Luider, TM; Osterhaus, AD; Reedijk, ML; van Kampen, JJ | 1 |
| Chen, L; Chen, X; He, Z; Qin, L; You, J | 1 |
| Annaert, P; Augustijns, P; Camus, S; Ye, ZW | 1 |
| Alvar, J; Cañavate, C; Dagger, F; Moreno, J; Rangel, A; Saugar, JM; Valdivieso, E | 1 |
| Beghin, D; Farinotti, R; Forestier, F; Gavard, L; Gil, S; Guibourdenche, J; Noël-Hudson, MS | 1 |
| Fessel, WJ; Hellinger, J; Kaufman, D; Rhee, SY; Ruane, P; Shafer, RW; Shirvani, V; Taylor, J; Towner, W; Troia, P; Zolopa, A | 1 |
| Alder, J; Brown, HS; Houston, JB; Wilby, AJ | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Picchio, G; Spinosa-Guzman, S; Van De Casteele, T; Vanden Abeele, C | 1 |
| Andrews, S; Carlson, GA; Hanamsagar, R; Huang, Y; Ikezu, T; Kiyota, T; Lan, X; Peng, H; Swindells, S; Zheng, JC | 1 |
| Nsanzabana, C; Rosenthal, PJ | 1 |
| Appel, DI; Markowitz, JS; Peloquin, CA; Peterson, YK; Rhoades, JA; Zhu, HJ | 1 |
| Ahmed, I; Bégaud, B; Tubert-Bitter, P | 1 |
| Branquinha, MH; d'Avila-Levy, CM; Pedroso e Silva, CM; Santos, AL; Santos, LO; Vitório, BS | 1 |
| Branquinha, MH; Catanho, M; d'Avila-Levy, CM; Garcia-Gomes, AS; Santos, AL; Santos, LO; Sodre, CL | 1 |
| Bader, J; Driessen, C; Kraus, M; Müller-Ide, H; Overkleeft, H; Rückrich, T | 1 |
| Branquinha, MH; D Avila-Levy, CM; Menna-Barreto, RF; Sangenito, LS; Santos, AL | 1 |
| Bihani, SC; Ferrer, JL; Hosur, MV; Prashar, V | 1 |
| Baptista, LPR; Branquinha, MH; Castilho, VVS; d'Avila-Levy, CM; Gonçalves, KCS; Guimarães, AC; Menna-Barreto, RFS; Rebello, KM; Sangenito, LS; Santos, ALS; Santos, HLC | 1 |
| Amadori, L; Björkegren, JLM; Crane, HM; Crane, PK; Dudley, JT; Frades, I; Giannarelli, C; Koplev, S; Kovacic, JC; Peter, I; Readhead, B; Talukdar, HA | 1 |
| Hirano, Y; Komatsu, TS; Koyama, YM; Morimoto, G; Ohno, Y; Okimoto, N; Taiji, M | 1 |
31 review(s) available for nelfinavir and saquinavir
| Article | Year |
|---|---|
Protease inhibitors: current status and future prospects.
Topics: Animals; Aspartic Acid Endopeptidases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Metalloendopeptidases; Models, Molecular; Protease Inhibitors; Serine Endopeptidases; Serine Proteinase Inhibitors | 2000 |
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
Topics: Animals; Apoproteins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Drug Interactions; Heme; Humans; Models, Biological; Pharmacokinetics; Structure-Activity Relationship; Time Factors | 2012 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
HIV-1 protease inhibitors. A review for clinicians.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Nelfinavir; Ritonavir; Saquinavir; Viral Load | 1997 |
Human immunodeficiency virus type 1 protease inhibitors.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Interactions; Drug Resistance; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Nelfinavir; Ritonavir; RNA, Viral; Saquinavir; Sulfonic Acids | 1997 |
A 'second life' agenda. Psychiatric research issues raised by protease inhibitor treatments for people with the human immunodeficiency virus or the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Attitude to Health; Drug Approval; Drug Costs; Drug Interactions; Health Policy; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Life Style; Nelfinavir; Primary Prevention; Ritonavir; Saquinavir; United States; United States Food and Drug Administration; Viral Load | 1997 |
[Clinical application of HIV protease inhibitors].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Therapy, Combination; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir | 1998 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Resistance to human immunodeficiency virus type 1 protease inhibitors.
Topics: Carbamates; Drug Resistance; Furans; HIV Protease; HIV Protease Inhibitors; Indinavir; Nelfinavir; Pyridines; Pyrones; Ritonavir; Saquinavir; Structure-Activity Relationship; Sulfonamides | 1998 |
Type 2 diabetes in association with HIV-1 protease inhibitors in HIV-infected patients.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Retina; Retinal Diseases; Ritonavir; Saquinavir | 1998 |
Development of HIV protease inhibitors: a survey.
Topics: Anti-HIV Agents; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Structure-Activity Relationship | 1998 |
Simultaneous use of two protease inhibitors in HIV infection.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir | 1999 |
Drug interactions of HIV protease inhibitors.
Topics: Anti-Infective Agents; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 1999 |
HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.
Topics: Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Indinavir; Lipodystrophy; Nelfinavir; Ritonavir; Saquinavir | 1999 |
[HIV protease inhibitors: drug interactions].
Topics: Anti-HIV Agents; Contraindications; Drug Interactions; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Risk Factors; Ritonavir; Saquinavir | 1999 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
HIV protease as a target for retrovirus vector-mediated gene therapy.
Topics: Amino Acid Sequence; Carbamates; Furans; Genetic Therapy; Genetic Vectors; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lentivirus; Models, Molecular; Molecular Structure; Nelfinavir; Retroviridae; Ritonavir; Saquinavir; Sulfonamides; Transfection | 2000 |
Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Binding Sites; Carbamates; Clinical Trials as Topic; Computer-Aided Design; Crystallography, X-Ray; Drug Design; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrones; Randomized Controlled Trials as Topic; Ritonavir; Saquinavir; Sulfonamides | 2000 |
The choice of HIV protease inhibitor: indinavir is currently the best option.
Topics: Clinical Trials as Topic; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Treatment Outcome | 1999 |
Ongoing trials in HIV protease inhibitors.
Topics: Carbamates; Clinical Trials as Topic; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; United States; United States Food and Drug Administration | 2000 |
Pharmacology and clinical experience with saquinavir.
Topics: Biological Availability; CD4 Lymphocyte Count; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Randomized Controlled Trials as Topic; Ritonavir; Saquinavir; Virus Replication | 2001 |
[Resistance to protease inhibitors].
Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Mutation; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2001 |
Penetration of HIV-1 protease inhibitors into CSF and semen.
Topics: Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Ritonavir; Saquinavir; Semen; Sulfonamides; Viral Load | 2000 |
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir | 2002 |
Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection.
Topics: Adolescent; Area Under Curve; Blood Proteins; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Randomized Controlled Trials as Topic; Saquinavir | 2002 |
Peptidomimetic inhibitors of HIV protease.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane | 2004 |
Quality control of protease inhibitors.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides | 2008 |
Anti-HIV drugs for cancer therapeutics: back to the future?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cidofovir; Cytosine; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Neoplasms; Organophosphonates; Receptors, CXCR4; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Zidovudine | 2009 |
Aspartic peptidases of human pathogenic trypanosomatids: perspectives and trends for chemotherapy.
Topics: Aspartic Acid Proteases; HIV Protease Inhibitors; Humans; Nelfinavir; Protozoan Proteins; Saquinavir; Trypanocidal Agents; Trypanosoma; Trypanosomiasis | 2013 |
39 trial(s) available for nelfinavir and saquinavir
| Article | Year |
|---|---|
The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; RNA, Viral; Saquinavir | 1998 |
[Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results].
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nelfinavir; Pilot Projects; Saquinavir; Stavudine; Treatment Outcome; Viral Load | 1998 |
Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Topics: Adult; Anti-HIV Agents; Biological Availability; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Mixed Function Oxygenases; Nelfinavir; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Salvage Therapy; Saquinavir; Treatment Outcome; Viral Load; Viremia | 1999 |
Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Predictive Value of Tests; Prospective Studies; Ritonavir; RNA, Viral; Saquinavir; Treatment Failure; Viral Load | 1999 |
Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons.
Topics: Adult; Drug Resistance; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Nevirapine; Polypharmacy; Prognosis; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir | 1999 |
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.
Topics: Adult; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Nelfinavir; Nevirapine; Phenotype; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir | 1999 |
Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Reverse Transcriptase Inhibitors; Salvage Therapy; Saquinavir; Stavudine; Viral Load | 1999 |
Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Diarrhea; Drug Therapy, Combination; Female; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Liver; Male; Middle Aged; Nausea; Nelfinavir; Reverse Transcriptase Inhibitors; Saquinavir; Stavudine | 2000 |
Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
Topics: Adult; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Prospective Studies; Ritonavir; RNA, Viral; Saquinavir; Viral Load | 2000 |
The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe.
Topics: Adult; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Pregnancy; RNA, Viral; Saquinavir | 2000 |
Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years.
Topics: Adult; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Cytomegalovirus Retinitis; Drug Therapy, Combination; Foscarnet; Ganciclovir; HIV Protease Inhibitors; Humans; Incidence; Indinavir; Nelfinavir; Outcome Assessment, Health Care; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 1999 |
Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; HIV Seronegativity; Humans; Kinetics; Lymph Nodes; Lymphocyte Activation; Middle Aged; Nelfinavir; Regression Analysis; Saquinavir; T-Lymphocyte Subsets; T-Lymphocytes; Time Factors | 2000 |
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Injections, Subcutaneous; Interleukin-2; Lamivudine; Lymphocyte Count; Male; Nelfinavir; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 2000 |
Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Protease Inhibitors; HIV Seropositivity; Humans; Male; Nelfinavir; Ritonavir; RNA, Viral; Saquinavir; Time Factors; Treatment Failure; Treatment Outcome | 2000 |
Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
Topics: Carbamates; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Phenotype; Protein Binding; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study.
Topics: Adult; Anticholesteremic Agents; Drug Tolerance; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hyperlipidemias; Indinavir; Male; Nelfinavir; Pilot Projects; Pravastatin; Ritonavir; Saquinavir; Treatment Outcome | 2000 |
Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nelfinavir; Organophosphonates; Prospective Studies; Ritonavir; RNA, Viral; Saquinavir | 2000 |
Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
Topics: Adult; Anti-HIV Agents; Antigens, Fungal; Antigens, Viral; Antiretroviral Therapy, Highly Active; Candida albicans; Carbamates; CD4 Lymphocyte Count; Chronic Disease; Cytomegalovirus; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Simplexvirus; Sulfonamides; T-Lymphocyte Subsets | 2000 |
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nelfinavir; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 2000 |
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Topics: Adult; Aged; Anti-HIV Agents; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Mutation; Nelfinavir; Nevirapine; Prospective Studies; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Treatment Failure; Viral Load | 2001 |
The ADAM study continued: maintenance therapy after 50 weeks of induction therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Stavudine; Time Factors; Treatment Outcome; Viral Load | 2001 |
The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Prospective Studies; Ritonavir; Saquinavir; Treatment Outcome; Viral Load | 2001 |
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.
Topics: Adult; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Ritonavir; Sample Size; Saquinavir; Stavudine; Zidovudine | 2001 |
Early results from SPICE study reported.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Europe; HIV Infections; Humans; Nelfinavir; Nucleosides; Saquinavir; Treatment Outcome | 1998 |
Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Treatment Outcome; Triglycerides | 2001 |
Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
Topics: Adult; Area Under Curve; Carbamates; CD4 Lymphocyte Count; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Furans; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; Male; Mixed Function Oxygenases; Nelfinavir; Orosomucoid; Saquinavir; Sulfonamides | 2001 |
Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen.
Topics: Adult; Aged; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease; HIV-1; Humans; Male; Middle Aged; Mutation; Nelfinavir; Prospective Studies; Protease Inhibitors; Reverse Transcriptase Inhibitors; Salvage Therapy; Saquinavir; Treatment Outcome; Viral Load | 2002 |
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Organophosphonates; Oxazines; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Saquinavir; Sulfonamides; Treatment Failure; Viral Load | 2002 |
Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
Topics: Adult; Biological Availability; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Mixed Function Oxygenases; Nelfinavir; Saquinavir; Sulfonamides | 2002 |
Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration.
Topics: Administration, Oral; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Models, Biological; Models, Chemical; Nelfinavir; Ritonavir; Saquinavir | 2002 |
Diurnal variation of plasma protease inhibitor concentrations.
Topics: Circadian Rhythm; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Ritonavir; Saquinavir | 2002 |
Sildenafil does not alter nelfinavir pharmacokinetics.
Topics: Adult; Area Under Curve; Chromatography, High Pressure Liquid; Drug Interactions; Drug Therapy, Combination; Erectile Dysfunction; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Piperazines; Purines; Ritonavir; Saquinavir; Sildenafil Citrate; Sulfones; Vasodilator Agents | 2003 |
Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
Topics: Anti-HIV Agents; Capsules; CD4 Lymphocyte Count; Drug Therapy, Combination; Follow-Up Studies; Gelatin; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Reverse Transcriptase Inhibitors; Saquinavir; Time Factors; Treatment Outcome; Virus Replication | 2003 |
Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.
Topics: Adult; Area Under Curve; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Administration Schedule; Drug Combinations; Female; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet | 2003 |
Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lactates; Male; Middle Aged; Nelfinavir; Nervous System Diseases; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Treatment Outcome | 2003 |
A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir | 2003 |
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Organophosphonates; Ritonavir; RNA, Viral; Saquinavir; Sex Factors | 2004 |
Quadruple-2 protease inhibitors (PI)-therapy does not accelerate viral decay and suppression in PI-naive HIV-1 infected patients with severe immunosuppression and high viral load as compared with standard triple therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunosuppression Therapy; Nelfinavir; Saquinavir; Viral Load | 2005 |
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Topics: Adamantane; Adult; Analysis of Variance; Atazanavir Sulfate; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Molecular Typing; Nelfinavir; Neuraminidase; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides; Viral Load | 2010 |
207 other study(ies) available for nelfinavir and saquinavir
| Article | Year |
|---|---|
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Intestinal Absorption; Male; Mice; Nelfinavir; Saquinavir | 1998 |
Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
Topics: Animals; Anti-HIV Agents; Crystallography, X-Ray; Dogs; Drug Design; HIV; HIV Protease Inhibitors; Molecular Structure; Mutation; Protein Binding; Urea; Virus Replication | 1998 |
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
Topics: Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Carrier Proteins; Genes, MDR; HeLa Cells; Histamine H1 Antagonists; Humans; LLC-PK1 Cells; Mice; Rats; Swine; Terfenadine; Tissue Distribution; Transfection; Vaccinia virus | 1999 |
Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Carbon Radioisotopes; Carrier Proteins; Dose-Response Relationship, Drug; Gene Expression; HeLa Cells; HIV Protease Inhibitors; Humans; Indinavir; Membrane Proteins; Multidrug Resistance-Associated Proteins; Nelfinavir; Organic Cation Transporter 1; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Messenger; Saquinavir; Tetraethylammonium; Tumor Cells, Cultured | 2000 |
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Brain; Caco-2 Cells; Dibenzocycloheptenes; HIV Protease Inhibitors; Humans; Inhibitory Concentration 50; Male; Mice; Quinolines; Testis | 2000 |
Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.
Topics: Anti-HIV Agents; Drug Design; HIV Protease Inhibitors; Thiazoles | 2000 |
Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Cell Line, Transformed; Colonic Neoplasms; Drug Resistance, Multiple; Furans; Gene Expression Regulation, Neoplastic; HIV Protease Inhibitors; Humans; Indinavir; Ivermectin; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Tumor Cells, Cultured; Verapamil; Vinblastine | 2000 |
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.
Topics: Animals; Antiviral Agents; Cattle; Cell Culture Techniques; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Haplorhini; HIV Protease Inhibitors; HIV-1; Humans; Indans; Male; Piperazines; Protein Binding; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Urinary Calculi | 2000 |
Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitution.
Topics: Amides; Cell Line; Cloning, Molecular; Crystallography, X-Ray; Drug Design; Escherichia coli; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indans; Models, Molecular; Mutation; Structure-Activity Relationship | 2001 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Structure-based design and synthesis of HIV-1 protease inhibitors employing beta-D-mannopyranoside scaffolds.
Topics: Aspartic Acid Endopeptidases; Binding Sites; Drug Design; HIV Protease Inhibitors; HIV-1; Inhibitory Concentration 50; Mannose; Molecular Conformation; Structure-Activity Relationship | 2002 |
Relationships between structure and interaction kinetics for HIV-1 protease inhibitors.
Topics: Biosensing Techniques; HIV Protease; HIV Protease Inhibitors; Kinetics; Protein Binding; Structure-Activity Relationship; Surface Plasmon Resonance; Urea | 2002 |
Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation.
Topics: Adenosine Triphosphate; Animals; Antibiotics, Antitubercular; Carrier Proteins; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA, Complementary; Estradiol; Genes, Reporter; Hepatocytes; Humans; In Vitro Techniques; Kinetics; Liver-Specific Organic Anion Transporter 1; Membrane Transport Proteins; Organic Anion Transporters, Sodium-Dependent; Organic Cation Transporter 1; Plasmids; Pregnane X Receptor; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rifampin; Symporters; Transcriptional Activation; Transfection | 2003 |
A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Topics: Binding Sites; Binding, Competitive; Catalysis; Drug Resistance, Viral; Enzyme Stability; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Models, Chemical; Mutagenesis, Site-Directed; Nelfinavir; Ritonavir; Saquinavir; Structure-Activity Relationship; Thermodynamics | 2003 |
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Indicators and Reagents; Mice; Models, Molecular; Rhodamines; Species Specificity; Swine | 2003 |
HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Cells, Cultured; Drug Resistance, Neoplasm; Gene Expression; HIV Protease Inhibitors; Humans; Indinavir; Mitoxantrone; Nelfinavir; Neoplasm Proteins; Ritonavir; Saquinavir; Tritium | 2004 |
Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.
Topics: Biosensing Techniques; Cells, Cultured; Cluster Analysis; HIV Protease; HIV Protease Inhibitors; HIV-1; Kinetics; Principal Component Analysis; Quantitative Structure-Activity Relationship; Virus Replication | 2004 |
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
Topics: Animals; Benzoxazoles; Binding Sites; Calorimetry; Cell Line; Crystallography, X-Ray; Dogs; Drug Resistance, Multiple, Viral; Drug Stability; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Microsomes, Liver; Models, Molecular; Rats; Rats, Wistar; Sulfonamides; Thermodynamics; Thiazoles | 2005 |
Early absorption and distribution analysis of antitumor and anti-AIDS drugs: lipid membrane and plasma protein interactions.
Topics: Absorption; Anti-HIV Agents; Antineoplastic Agents; Binding Sites; Biosensing Techniques; Blood Proteins; HIV Protease; HIV Protease Inhibitors; Humans; Kinetics; Lipids; Membranes, Artificial; Orosomucoid; Serum Albumin; Surface Plasmon Resonance; Taxoids | 2005 |
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
Topics: HIV Protease Inhibitors; Molecular Structure; Sulfonamides | 2006 |
Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.
Topics: Amino Acid Substitution; Atazanavir Sulfate; Binding Sites; Crystallography, X-Ray; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; Hydrophobic and Hydrophilic Interactions; Kinetics; Models, Molecular; Oligopeptides; Polymorphism, Genetic; Pyridines; Structure-Activity Relationship | 2006 |
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Crystallography, X-Ray; Darunavir; Drug Design; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Models, Molecular; Molecular Structure; Protein Conformation; Protein Structure, Tertiary; Stereoisomerism; Structure-Activity Relationship; Sulfonamides | 2006 |
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Genes, gag; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Mutation; Nelfinavir; Oligopeptides; Pyridines; Ritonavir; Saquinavir; Virus Replication | 2007 |
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Topics: Amino Acid Sequence; Drug Design; Drug Resistance, Multiple, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Sulfonamides; Urethane; Virus Replication | 2007 |
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
Topics: Amino Acid Sequence; Anti-HIV Agents; Cell Line; Cytopathogenic Effect, Viral; Drug Resistance, Viral; HIV Core Protein p24; HIV Protease Inhibitors; HIV-2; Humans; Lopinavir; Molecular Sequence Data; Mutagenesis, Site-Directed; Phenotype; Pyrimidinones; RNA-Directed DNA Polymerase; Virus Replication | 2007 |
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Cell Survival; Drug Resistance, Viral; Genotype; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Mutation; Phenotype; Sulfonamides; Viral Proteins | 2007 |
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Topics: Adenine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Chromatography, High Pressure Liquid; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Interactions; Epithelium; HIV Protease Inhibitors; Humans; Hydrolysis; Indicators and Reagents; Intestinal Absorption; Mass Spectrometry; Organophosphonates; Subcellular Fractions; Tenofovir | 2007 |
Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors.
Topics: Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; Drug Stability; HIV Protease Inhibitors; In Vitro Techniques; Magnetic Resonance Spectroscopy; Prodrugs; Valine | 2008 |
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
Topics: Animals; Dogs; Drug Design; Hepatocytes; HIV Protease Inhibitors; HIV-1; Humans; Molecular Structure; Mutation; Phenylbutyrates; Sensitivity and Specificity; Structure-Activity Relationship | 2008 |
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
Topics: Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Mutation; Phenotype; Pyrimidinones; Selection, Genetic; Serial Passage | 2008 |
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
Topics: Darunavir; HIV Protease; HIV Protease Inhibitors; HIV-2; Humans; Inhibitory Concentration 50; Lopinavir; Microbial Sensitivity Tests; Phenotype; Pyrimidinones; Saquinavir; Sulfonamides | 2008 |
Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo.
Topics: Animals; Antimalarials; Atazanavir Sulfate; Chloroquine; Drug Resistance; Drug Synergism; Female; HIV Protease Inhibitors; Humans; In Vitro Techniques; Lopinavir; Malaria; Mice; Nelfinavir; Oligopeptides; Plasmodium chabaudi; Plasmodium falciparum; Pyridines; Pyrimidinones; Ritonavir; Saquinavir | 2008 |
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
Topics: Boron Compounds; Crystallography, X-Ray; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Metals; Models, Molecular; Molecular Structure; Mutation | 2008 |
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
Topics: Amino Acid Sequence; Carbamates; Cyclopentanes; Dose-Response Relationship, Drug; Drug Resistance, Viral; Furans; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Sequence Data; Molecular Structure; Sulfonamides | 2009 |
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
Topics: Animals; Blood-Brain Barrier; Brain; Extracellular Fluid; Humans; Linear Models; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Synthesis of new thienyl ring containing HIV-1 protease inhibitors: promising preliminary pharmacological evaluation against recombinant HIV-1 proteases.
Topics: Asparagine; HIV Protease; HIV Protease Inhibitors; Mutation; Nelfinavir; Quinolines; Recombinant Proteins; Saquinavir; Stereoisomerism; Structure-Activity Relationship | 2010 |
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
Topics: Cell Line; Dimerization; Drug Resistance, Multiple, Viral; Furans; Genetic Variation; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Macrocyclic Compounds; Microbial Sensitivity Tests; Models, Molecular; Structure-Activity Relationship; Virus Replication | 2010 |
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
Topics: Antiviral Agents; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mutation; Pyrimidinones; Sulfonamides | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.
Topics: Cell Line; Drug Resistance, Viral; Enzyme-Linked Immunosorbent Assay; gag Gene Products, Human Immunodeficiency Virus; HIV Antigens; HIV Protease Inhibitors; HIV-1; Humans; Mutagenesis, Site-Directed; Virus Replication | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Experimental and 'in silico' analysis of the effect of pH on HIV-1 protease inhibitor affinity: implications for the charge state of the protein ionogenic groups.
Topics: Biosensing Techniques; Catalytic Domain; HIV Protease; HIV Protease Inhibitors; HIV-1; Hydrogen-Ion Concentration; Kinetics; Models, Molecular; Surface Plasmon Resonance | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir.
Topics: Aspartic Acid Endopeptidases; Crystallography, X-Ray; Dose-Response Relationship, Drug; HIV Protease Inhibitors; Indinavir; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2014 |
Development of an
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Cell Line; Computer Simulation; Endothelial Cells; Gene Knockout Techniques; Humans; Organic Chemicals; Rats, Transgenic | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Microbial; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Kinetics; Mutagenesis; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Sulfonic Acids | 1996 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Saquinavir | 1997 |
Drug interactions and protease inhibitor therapy in the treatment of HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Patient Education as Topic; Primary Nursing; Ritonavir; Saquinavir | 1998 |
[Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released].
Topics: Diabetes Complications; Diabetes Mellitus; HIV Infections; HIV Protease Inhibitors; Humans; Hyperglycemia; Indinavir; Nelfinavir; Ritonavir; Saquinavir | 1997 |
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
Topics: Adult; Anti-HIV Agents; Body Composition; Cross-Sectional Studies; Diabetes Mellitus; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Indinavir; Insulin Resistance; Lipodystrophy; Male; Nelfinavir; Risk Factors; Ritonavir; Saquinavir; Syndrome | 1998 |
HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy.
Topics: Amino Acid Substitution; Carbamates; Clinical Trials as Topic; Databases, Factual; DNA, Viral; Furans; Genetic Linkage; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Methionine; Nelfinavir; Phenotype; Polymerase Chain Reaction; Ritonavir; Saquinavir; Sulfonamides; Valine | 1998 |
Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
Topics: Anti-HIV Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cell Survival; Daunorubicin; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; HIV Protease Inhibitors; Humans; Indinavir; Leukemia, Erythroblastic, Acute; Nelfinavir; Paclitaxel; Ritonavir; Saquinavir; Sarcoma; Tumor Cells, Cultured; Uterine Neoplasms; Vinblastine | 1998 |
HIV-1 peripheral neuropathy and combination antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Nelfinavir; Nevirapine; Peripheral Nervous System Diseases; Saquinavir; Zidovudine | 1998 |
Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.
Topics: Adaptation, Biological; Amino Acid Substitution; Animals; Anti-HIV Agents; Cells, Cultured; Drug Resistance, Microbial; HIV Protease Inhibitors; HIV-1; Humans; Mice; Mutagenesis, Site-Directed; Nelfinavir; Saquinavir; Tumor Cells, Cultured; Virus Replication | 1999 |
Liposuction for protease-inhibitor-associated lipodystrophy.
Topics: HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipectomy; Lipodystrophy; Male; Middle Aged; Nelfinavir; Saquinavir | 1999 |
Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Reproducibility of Results; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet | 1999 |
Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors.
Topics: Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Genetic Variation; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Sequence Data; Nelfinavir; Ritonavir; Saquinavir | 1999 |
Dynamic correlation of apoptosis and immune activation during treatment of HIV infection.
Topics: Adolescent; Adult; Anti-HIV Agents; Apoptosis; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Drug Therapy, Combination; fas Receptor; HIV Infections; HIV Protease Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Middle Aged; Nelfinavir; Nucleosides; Reverse Transcriptase Inhibitors; Saquinavir; T-Lymphocytes | 1999 |
Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Retrospective Studies; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir; Treatment Failure; Viral Load | 1999 |
A new contained human immunodeficiency virus type 1 host cell system for evaluation of antiviral activities of interferons and other agents in vitro.
Topics: Anti-HIV Agents; CD4 Antigens; Drug Evaluation, Preclinical; Gene Expression; Gene Products, rev; Gene Products, tat; HeLa Cells; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Interferon-alpha; Nelfinavir; rev Gene Products, Human Immunodeficiency Virus; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; tat Gene Products, Human Immunodeficiency Virus; Zidovudine | 1999 |
Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
Topics: Adult; Anti-HIV Agents; Arteriosclerosis; Child; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Indinavir; Lipids; Lipoprotein(a); Lipoproteins; Logistic Models; Male; Nelfinavir; Risk Factors; Ritonavir; Saquinavir; Thyrotropin | 1999 |
Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: a case series.
Topics: Adolescent; Adult; Aged; Databases, Factual; Female; Hemophilia A; Hemorrhage; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Saquinavir; Treatment Outcome; United States; United States Food and Drug Administration; Zidovudine | 1999 |
Effect of protease inhibitors on the sense of taste.
Topics: Adult; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Ritonavir; Saquinavir; Taste; Taste Disorders | 1999 |
Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Flow Cytometry; Fluorescent Dyes; HIV Protease Inhibitors; Humans; Indinavir; Lymphocytes; Nelfinavir; Rhodamine 123; Ritonavir; Saquinavir; Temperature; Verapamil | 1999 |
Activity of the combination of nelfinavir and saquinavir against human immunodeficiency virus after failure of prior protease inhibitor therapy.
Topics: Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Retrospective Studies; Salvage Therapy; Saquinavir; Treatment Failure; Treatment Outcome | 1999 |
Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual.
Topics: Administration, Oral; Anti-HIV Agents; Drug Therapy, Combination; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Nevirapine; Peptides; Reverse Transcriptase Inhibitors; Saquinavir | 1999 |
Two possible pathways for acquisition of mutations related to nelfinavir resistance.
Topics: Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; Humans; Mutation; Nelfinavir; Ritonavir; Saquinavir | 1999 |
Pharmacokinetic interactions between HIV-protease inhibitors in rats.
Topics: Acquired Immunodeficiency Syndrome; Animals; Drug Interactions; Drug Therapy, Combination; HIV Protease Inhibitors; Indinavir; Male; Nelfinavir; Rats; Rats, Wistar; Ritonavir; Saquinavir | 1999 |
Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma.
Topics: Chromatography, High Pressure Liquid; Humans; Indinavir; Mass Spectrometry; Nelfinavir; Reproducibility of Results; Ritonavir; Saquinavir | 2000 |
Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases.
Topics: Adult; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Risk Factors; Ritonavir; Saquinavir; Venous Thrombosis | 1999 |
The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir but not indinavir impair the epithelial barrier in the human intestinal cell line HT-29/B6.
Topics: HIV Protease Inhibitors; HT29 Cells; Humans; Indinavir; Intestinal Mucosa; Ion Transport; Nelfinavir; Ritonavir; Saquinavir | 1999 |
Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection.
Topics: Adolescent; Child; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Prognosis; Retrospective Studies; Ritonavir; Salvage Therapy; Saquinavir; Treatment Outcome | 2000 |
Kinetic analysis of the interaction between HIV-1 protease and inhibitors using optical biosensor technology.
Topics: Drug Design; Enzymes, Immobilized; HIV Protease; HIV Protease Inhibitors; In Vitro Techniques; Indinavir; Kinetics; Molecular Weight; Nelfinavir; Ritonavir; Saquinavir; Surface Plasmon Resonance | 2000 |
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Dideoxynucleosides; Furans; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lymph Nodes; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Stavudine; Sulfonamides; Time Factors; Viral Load; Viremia; Zidovudine | 2000 |
In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors.
Topics: Antidepressive Agents, Second-Generation; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Ketoconazole; Microsomes, Liver; Nelfinavir; Oxidoreductases, N-Demethylating; Piperazines; Ritonavir; Saquinavir; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Trazodone | 2000 |
The efficacy and tolerability of combination antiretroviral therapy in pregnancy: infant and maternal outcome.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Infant; Lamivudine; Male; Nelfinavir; Nevirapine; Pregnancy; Pregnancy Outcome; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Treatment Outcome; Zidovudine | 2000 |
Decreased HIV-associated T cell apoptosis by HIV protease inhibitors.
Topics: Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Didanosine; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Jurkat Cells; Nelfinavir; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; T-Lymphocytes; Viral Load; Zidovudine | 2000 |
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction.
Topics: Alkynes; Benzoxazines; Calibration; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oxazines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2000 |
In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii.
Topics: Animals; Cell Line; HIV Protease Inhibitors; Humans; Indinavir; Lung; Male; Microbial Sensitivity Tests; Nelfinavir; Pepstatins; Pneumocystis; Pneumocystis Infections; Rats; Rats, Sprague-Dawley; Saquinavir | 2000 |
Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Cohort Studies; Confidence Intervals; Drug Monitoring; Female; Follow-Up Studies; HIV Protease Inhibitors; HIV Seropositivity; Humans; Incidence; Indinavir; Italy; Male; Middle Aged; Multivariate Analysis; Nelfinavir; Prospective Studies; Risk Factors; Ritonavir; Saquinavir | 2000 |
Hyperlipidemia associated with the use of protease inhibitors.
Topics: Adult; Anti-HIV Agents; Cholesterol; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Indinavir; Male; Nelfinavir; Ritonavir; Saquinavir; Triglycerides | 2000 |
Simultaneous determination of the five HIV-protease inhibitors: amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by solid-phase extraction and column liquid chromatography.
Topics: Carbamates; Chromatography, Liquid; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Carbamates; Dietary Fats; Drug Interactions; Furans; HIV Protease Inhibitors; Indinavir; Injections, Subcutaneous; Insulin; Liver; Male; Mice; Mice, Inbred AKR; Nelfinavir; Saquinavir; Sulfonamides | 2000 |
Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.
Topics: Amino Acid Sequence; Amino Acid Substitution; Carbamates; Codon; Drug Resistance, Microbial; Furans; Global Health; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Sequence Data; Mutation; Nelfinavir; Phylogeny; Ritonavir; Saquinavir; Sulfonamides | 2000 |
HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.
Topics: Adipocytes; Animals; Azo Compounds; Bexarotene; Carbamates; Carrier Proteins; Cell Differentiation; Cells, Cultured; Coloring Agents; Fatty Acid-Binding Proteins; Furans; HIV Protease Inhibitors; Indinavir; Insulin; Lipolysis; Lipoprotein Lipase; Nelfinavir; Neoplasm Proteins; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Ritonavir; RNA, Messenger; Rosiglitazone; Saquinavir; Stem Cells; Sulfonamides; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2000 |
Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants.
Topics: Drug Resistance, Microbial; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Mutagenesis, Site-Directed; Mutation; Nelfinavir; Polymerase Chain Reaction; Ritonavir; Saquinavir; Virus Replication | 2000 |
Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant.
Topics: Amino Acid Substitution; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Drug Resistance, Microbial; Entropy; Enzyme Stability; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Mutagenesis, Site-Directed; Nelfinavir; Phenylalanine; Protons; Ritonavir; Saquinavir; Thermodynamics; Valine | 2000 |
Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
Topics: Animals; Chromatography, High Pressure Liquid; Drug Interactions; Drug Therapy, Combination; HIV Protease Inhibitors; Indinavir; Male; Microsomes, Liver; Nelfinavir; Rats; Rats, Wistar; Saquinavir | 2000 |
HIV protease inhibitors stimulate hepatic triglyceride synthesis.
Topics: Acyltransferases; Animals; Blood Glucose; Carbon Radioisotopes; Cholesterol; Diacylglycerol O-Acyltransferase; Fasting; Fatty Acid Synthases; Fatty Acids; HIV Protease Inhibitors; Hyperlipidemias; Liver; Male; Mice; Mice, Inbred AKR; Nelfinavir; Nicotinic Acids; Postprandial Period; Receptors, Retinoic Acid; Retinoid X Receptors; Ritonavir; RNA, Messenger; Saquinavir; Tetrahydronaphthalenes; Transcription Factors; Triglycerides; Tumor Cells, Cultured | 2000 |
Induction-maintenance (5 --> 3 drugs) in HIV-infected patients with high viral load.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV Infections; Humans; Lamivudine; Nelfinavir; Nitriles; Prospective Studies; Pyrrolidines; Remission Induction; Saquinavir; Stavudine; Treatment Outcome; Viral Load | 2000 |
Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance, Microbial; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Mutation; Nelfinavir; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Saquinavir; Treatment Failure; Zidovudine | 2001 |
Effects of HIV protease inhibitors on barrier function in the human intestinal cell line HT-29/B6.
Topics: Acquired Immunodeficiency Syndrome; Colon; Diarrhea; HIV Protease Inhibitors; HT29 Cells; Humans; Indinavir; Intestinal Absorption; Intestinal Mucosa; Nelfinavir; Ritonavir; Saquinavir | 2000 |
Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography.
Topics: Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; HIV Protease Inhibitors; Humans; Indicators and Reagents; Indinavir; Nelfinavir; Reference Standards; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet | 2001 |
The safety and antiviral effect of protease inhibitors in children.
Topics: Adolescent; Blood Chemical Analysis; CD4 Lymphocyte Count; Child; Child, Preschool; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Infant; Male; Nelfinavir; Ritonavir; RNA, Viral; Saquinavir; Viral Load | 2001 |
Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes.
Topics: Adult; Amino Acid Sequence; Catalysis; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Sequence Data; Nelfinavir; Protein Structure, Secondary; Ritonavir; Saquinavir; Uganda | 2001 |
Abacavir (1592) with protease inhibitors in potent antiretroviral activity.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Viral Load | 1998 |
Viracept combination studies.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Humans; Indinavir; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine | 1998 |
Protease inhibitor trials moving to next phase.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Virus Replication | 1995 |
Protease inhibitors and prevention of cross resistance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Carbamates; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nelfinavir; Pyridines; Quinolines; Saquinavir; Sulfonamides; Zalcitabine; Zidovudine | 1995 |
Anti-HIV agents at ICAAC.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Cidofovir; Cytomegalovirus Retinitis; Cytosine; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Isoquinolines; Kidney; Mutation; Nelfinavir; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonic Acids; Treatment Failure; Viral Load | 1996 |
Nelfinavir is number 4 -- but should it bat cleanup, or lead off?
Topics: Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Mutation; Nelfinavir; Ritonavir; Saquinavir; Sulfonic Acids | 1997 |
Update on antivirals.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dosage Forms; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 1997 |
Combinations of protease inhibitors.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Viral Load | 1998 |
Antivirals and children.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Clinical Trials as Topic; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Nelfinavir; Practice Guidelines as Topic; Ritonavir; Saquinavir; Viral Load | 1998 |
Salvage therapy studies.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Salvage Therapy; Saquinavir; Viral Load | 1998 |
Any toxic relief in sight? The induction/maintenance approach to therapy.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Nelfinavir; Saquinavir; Stavudine; T-Lymphocytes; Viral Load; Virus Replication | 1998 |
Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport, Active; Cell Line; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Multidrug Resistance-Associated Proteins; Nelfinavir; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; Saquinavir | 2001 |
Design and synthesis of a conformationally restricted trans peptide isostere based on the bioactive conformations of saquinavir and nelfinavir.
Topics: Anti-HIV Agents; HIV Protease Inhibitors; Indicators and Reagents; Magnetic Resonance Spectroscopy; Molecular Conformation; Nelfinavir; Saquinavir; Spectrometry, Mass, Electrospray Ionization | 2001 |
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.
Topics: Adult; Calibration; Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2001 |
Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology.
Topics: Amino Acid Substitution; Biosensing Techniques; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Kinetics; Mathematics; Mutation; Nelfinavir; Protein Binding; Ritonavir; Saquinavir; Thermodynamics | 2001 |
Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.
Topics: Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Reference Standards; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides | 2001 |
CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cytomegalovirus Retinitis; Follow-Up Studies; HIV Infections; Humans; Indinavir; Longitudinal Studies; Middle Aged; Nelfinavir; Prevalence; Protease Inhibitors; Ritonavir; Saquinavir; Viral Load | 2001 |
The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
Topics: Adipose Tissue; Adult; Aged; Cholesterol; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Indinavir; Male; Middle Aged; Nelfinavir; Retrospective Studies; Ritonavir; Saquinavir; Triglycerides | 2001 |
Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection.
Topics: Administration, Oral; Adolescent; Antiretroviral Therapy, Highly Active; Capsules; Child; Child, Preschool; Female; Gelatin; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Prognosis; Reverse Transcriptase Inhibitors; Saquinavir | 2001 |
HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
Topics: Adult; Antigens, CD34; Antiretroviral Therapy, Highly Active; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Fluorescent Dyes; Hematopoietic Stem Cells; HIV Infections; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Lymphocytes; Male; Nelfinavir; Rhodamine 123; Ritonavir; RNA, Viral; Saquinavir | 2001 |
Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay.
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, Liquid; Cyclopropanes; Delavirdine; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Indinavir; Mass Spectrometry; Nelfinavir; Nevirapine; Oxazines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides | 2001 |
High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid e
Topics: Calibration; Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Nevirapine; Reference Standards; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides | 2001 |
Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss.
Topics: Apoptosis; Caspases; HIV Protease Inhibitors; Humans; Intracellular Membranes; Jurkat Cells; Membrane Potentials; Mitochondria; Nelfinavir; Ritonavir; Saquinavir; Tumor Cells, Cultured; Zidovudine | 2001 |
P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport; CD4-Positive T-Lymphocytes; Cell Line; Drug Resistance, Microbial; Drug Resistance, Multiple; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Multidrug Resistance-Associated Proteins; Nelfinavir; Ritonavir; Saquinavir | 2001 |
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Cohort Studies; Drug Administration Schedule; Female; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Nevirapine; Odds Ratio; Patient Compliance; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir; Surveys and Questionnaires | 2001 |
Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
Topics: Carbamates; Chromatography, High Pressure Liquid; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Pyrimidinones; Reproducibility of Results; Ritonavir; Saquinavir; Sulfonamides | 2001 |
Synthesis and anti-HIV activity of glucose-containing prodrugs derived from saquinavir, indinavir and nelfinavir.
Topics: Carbamates; Cell Survival; Cross-Linking Reagents; Esters; Glucose; Half-Life; HIV Protease Inhibitors; HIV-1; Humans; Hydrolysis; Indinavir; Nelfinavir; Prodrugs; Saquinavir; Tumor Cells, Cultured | 2001 |
Drugs for HIV infection.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dose-Response Relationship, Drug; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Saquinavir; Stavudine; Zidovudine | 2001 |
Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Disease Progression; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Ritonavir; RNA, Viral; Saquinavir; Time Factors; Treatment Failure; Viremia | 2002 |
CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.
Topics: Adult; Biological Availability; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Complementary; Enzyme Inhibitors; Female; Gene Expression; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Ketoconazole; Kinetics; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Microsomes, Liver; Mixed Function Oxygenases; Nelfinavir; Ritonavir; Saquinavir | 2002 |
In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Carbamates; Chromatography, High Pressure Liquid; Drug Interactions; Furans; HIV Protease Inhibitors; In Vitro Techniques; Indinavir; Male; Microsomes, Liver; Nelfinavir; Rats; Rats, Wistar; Saquinavir; Sulfonamides; Time Factors | 2002 |
Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oxazines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Select HIV protease inhibitors alter bone and fat metabolism ex vivo.
Topics: Adipocytes; Animals; Animals, Newborn; Bone and Bones; Calcium; Carbamates; Cells, Cultured; Down-Regulation; Fats; Furans; Glycoproteins; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mesoderm; Nelfinavir; Osteoblasts; Osteoclasts; Osteoprotegerin; Pyrimidinones; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Ritonavir; Saquinavir; Skull; Stem Cells; Sulfonamides | 2002 |
The utility of inhibitory quotients in determining the relative potency of protease inhibitors.
Topics: Carbamates; Drug Evaluation; Furans; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance.
Topics: Acquired Immunodeficiency Syndrome; Binding Sites; Biological Evolution; Computational Biology; Computer Simulation; Computer-Aided Design; Drug Design; Drug Resistance, Viral; Drug Therapy, Combination; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Models, Molecular; Mutation; Nelfinavir; Ritonavir; Saquinavir | 2002 |
High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitoring; Furans; HIV Infections; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Male sexual dysfunction associated with antiretroviral therapy.
Topics: Adolescent; Adult; Aged; Cohort Studies; Erectile Dysfunction; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Managed Care Programs; Middle Aged; Nelfinavir; New England; Retrospective Studies; Ritonavir; Saquinavir | 2002 |
Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
Topics: Africa; Amides; Amino Acid Substitution; Anti-HIV Agents; Calorimetry; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Kinetics; Mutagenesis, Site-Directed; Nelfinavir; Phenotype; Polymorphism, Genetic; Recombinant Proteins; Ritonavir; Saquinavir; Thermodynamics; Thiazoles | 2002 |
Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
Topics: Animals; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Furans; Half-Life; HIV Protease Inhibitors; Indinavir; Intestinal Mucosa; Liver; Male; Microsomes, Liver; Nelfinavir; Rats; Rats, Wistar; Saquinavir; Sulfonamides | 2002 |
Pharmacokinetics of saquinavir in children during long term treatment.
Topics: Biological Availability; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Long-Term Care; Male; Nelfinavir; Prospective Studies; Saquinavir; Treatment Outcome | 2002 |
Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS.
Topics: Carbamates; Chromatography, Liquid; Furans; Gas Chromatography-Mass Spectrometry; HIV Protease Inhibitors; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Simple and rapid high-performance liquid chromatographic method for nelfinavir, M8 nelfinavir metabolite, ritonavir and saquinavir assay in plasma.
Topics: Chromatography, High Pressure Liquid; HIV Protease Inhibitors; Humans; Nelfinavir; Reference Standards; Ritonavir; Saquinavir; Sensitivity and Specificity | 2002 |
Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.
Topics: Absorptiometry, Photon; Acquired Immunodeficiency Syndrome; Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Body Composition; HIV Protease Inhibitors; Homeostasis; Humans; Indinavir; Insulin; Leptin; Lipids; Lipodystrophy; Magnetic Resonance Imaging; Male; Middle Aged; Nelfinavir; Ritonavir; Saquinavir | 2002 |
Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers.
Topics: Biological Transport; Caco-2 Cells; Epithelial Cells; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Prodrugs; Saquinavir | 2002 |
Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors.
Topics: Adipocytes; Cell Line; Deoxyglucose; Drug Administration Schedule; Fibroblasts; Glucose Transporter Type 1; HIV Protease Inhibitors; Humans; Indinavir; Insulin Resistance; Lipolysis; Monosaccharide Transport Proteins; Muscle, Skeletal; Nelfinavir; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Saquinavir | 2003 |
Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats.
Topics: Animals; Carbamates; Drug Interactions; Furans; Indinavir; Infusions, Intravenous; Intestinal Absorption; Male; Microsomes, Liver; Nelfinavir; Rats; Rats, Wistar; Saquinavir; Sulfonamides | 2003 |
Inhibition of TNF-alpha mediated cell death by HIV-1 specific protease inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Drug Interactions; fas Receptor; HIV Protease Inhibitors; Humans; Indinavir; Jurkat Cells; Nelfinavir; Ritonavir; Saquinavir; Tumor Necrosis Factor-alpha; U937 Cells | 2003 |
Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; Heparin; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oxazines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides | 2003 |
Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Chromatography, High Pressure Liquid; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 2003 |
Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors.
Topics: Adult; Arteriosclerosis; Biomarkers; Black People; C-Reactive Protein; Calcium; Cholesterol; Coronary Artery Disease; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Male; Nelfinavir; Pyrimidinones; Ritonavir; Saquinavir | 2003 |
Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir, and nelfinavir in children and adults.
Topics: Adolescent; Adult; Child; Child, Preschool; Chromatography, High Pressure Liquid; Drug Monitoring; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir | 2003 |
Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.
Topics: 3T3 Cells; Adipocytes; Animals; Carbamates; Cell Differentiation; Cell Line; Enzyme-Linked Immunosorbent Assay; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Mice; Mice, Inbred Strains; Nelfinavir; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides | 2003 |
Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir and nelfinavir in children and adults.
Topics: Adult; Child; Chromatography, High Pressure Liquid; Drug Monitoring; Female; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Ritonavir; Saquinavir | 2003 |
Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity.
Topics: Anti-HIV Agents; Cell Line; Half-Life; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Magnetic Resonance Spectroscopy; Molecular Structure; Nelfinavir; Prodrugs; Saquinavir | 2004 |
In vitro studies of the effects of HAART drugs and excipients on activity of digestive enzymes.
Topics: Antiretroviral Therapy, Highly Active; Excipients; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Reverse Transcriptase Inhibitors; Saquinavir | 2004 |
Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus.
Topics: Adult; Amniotic Fluid; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Maternal-Fetal Exchange; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Saquinavir; Sulfonamides | 2004 |
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Chronic Disease; Drug Therapy, Combination; Female; Hepatitis; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Liver; Lopinavir; Male; Nelfinavir; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Saquinavir; Treatment Outcome | 2004 |
Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
Topics: Carbamates; Cell Line; Furans; Glucose; HIV Protease Inhibitors; Humans; Indinavir; Insulin; Insulin Receptor Substrate Proteins; Insulin Secretion; Intracellular Signaling Peptides and Proteins; Islets of Langerhans; Nelfinavir; Phosphoproteins; Phosphorylation; Ritonavir; Saquinavir; Signal Transduction; Stimulation, Chemical; Sulfonamides; Time Factors | 2004 |
Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Hepatitis; HIV Infections; Humans; Indinavir; Liver Function Tests; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Zidovudine | 2005 |
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Calibration; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Specimen Handling; Spectrophotometry, Ultraviolet; Sulfonamides | 2005 |
The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function.
Topics: HIV Protease Inhibitors; HL-60 Cells; Humans; Nelfinavir; Proteasome Endopeptidase Complex; Proteins; Reverse Transcriptase Inhibitors; Saquinavir; Ubiquitin | 2005 |
Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries.
Topics: Animals; Bradykinin; Carbamates; Coronary Vessels; Down-Regulation; Furans; HIV Protease Inhibitors; Indinavir; Methionine; Muscle Contraction; Muscle, Smooth, Vascular; Myography; Nelfinavir; Nitric Oxide Synthase; Organ Culture Techniques; Ritonavir; RNA, Messenger; Saquinavir; Selenium Compounds; Sulfonamides; Superoxides; Swine; Vasomotor System | 2005 |
HIV-1 protease inhibitors and cytomegalovirus vMIA induce mitochondrial fragmentation without triggering apoptosis.
Topics: Apoptosis; Calcium; Ceramides; Cytomegalovirus; Giant Cells; HeLa Cells; HIV Protease Inhibitors; Humans; Hydrogen Peroxide; Immediate-Early Proteins; Inhibitor of Apoptosis Proteins; Macrophage Inflammatory Proteins; Mitochondria; Nelfinavir; Ritonavir; Saquinavir; Tumor Suppressor Protein p53; Viral Proteins | 2006 |
The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir induce apoptosis and decrease barrier function in human intestinal epithelial cells.
Topics: Adult; Aged; Apoptosis; Cells, Cultured; Colon; Enzyme-Linked Immunosorbent Assay; Female; HIV Protease Inhibitors; Humans; Intestinal Mucosa; L-Lactate Dehydrogenase; Male; Middle Aged; Nelfinavir; Nucleosomes; Ritonavir; Saquinavir | 2005 |
Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Topics: Aryl Hydrocarbon Hydroxylases; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Furans; HIV Protease Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Indinavir; Isoenzymes; Kinetics; Nelfinavir; Recombinant Proteins; Ritonavir; Saquinavir; Sulfonamides; Testosterone | 2006 |
Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.
Topics: Adult; Anti-HIV Agents; beta 2-Microglobulin; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Immunoglobulin G; Male; Middle Aged; Nelfinavir; Neopterin; RNA, Viral; Saquinavir | 2006 |
Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.
Topics: Carbamates; Codon; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Mutation; Nelfinavir; Phenotype; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides | 2006 |
Establishment of a new cell line inducibly expressing HIV-1 protease for performing safe and highly sensitive screening of HIV protease inhibitors.
Topics: Cell Line; Doxycycline; Drug Evaluation, Preclinical; Gene Expression Regulation; Green Fluorescent Proteins; HIV Protease; HIV Protease Inhibitors; Humans; Nelfinavir; Recombinant Fusion Proteins; Saquinavir; Sensitivity and Specificity | 2006 |
Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; British Columbia; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Nelfinavir; Patient Compliance; Pyrimidinones; Ritonavir; Saquinavir; Viral Load | 2006 |
Secretory aspartyl peptidase activity from mycelia of the human fungal pathogen Fonsecaea pedrosoi: effect of HIV aspartyl proteolytic inhibitors.
Topics: Ascomycota; Culture Media; Enzyme Activation; Fungal Proteins; HIV Protease Inhibitors; Humans; Hydrogen-Ion Concentration; Indinavir; Mycelium; Nelfinavir; Pepstatins; Peptide Hydrolases; Ritonavir; Saquinavir; Time Factors | 2006 |
Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir
Topics: Atazanavir Sulfate; Calibration; Carbamates; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Fluorescence; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides; Ultraviolet Rays | 2007 |
An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet; Sulfonamides | 2007 |
Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors.
Topics: Bayes Theorem; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Sequence Data; Mutation; Nelfinavir; Saquinavir | 2007 |
Detection of HIV protease inhibitors in alveolar epithelial lining fluid: relevance for modulation of pneumocystis infection in the course of HAART.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Antiretroviral Therapy, Highly Active; Bronchoalveolar Lavage Fluid; Bronchoscopy; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Pneumocystis carinii; Pneumocystis Infections; Pyridines; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2006 |
High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Molecular Structure; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides; Time Factors | 2007 |
Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.
Topics: Adult; Anti-HIV Agents; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Ritonavir; Saquinavir | 2007 |
HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts.
Topics: Alkaline Phosphatase; Calcium; Cell Line; Down-Regulation; Gene Expression Profiling; Gene Expression Regulation; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oligonucleotide Array Sequence Analysis; Osteoblasts; Ritonavir; Saquinavir; Tissue Inhibitor of Metalloproteinase-3; Up-Regulation | 2007 |
Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir.
Topics: Aspartic Acid Endopeptidases; Cell Survival; Cells, Cultured; Cerebral Arteries; Cerebral Veins; Endothelial Cells; Frontal Lobe; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oxidative Stress; Phosphorylation; Proto-Oncogene Proteins; Reactive Oxygen Species; Receptor, Notch1; Receptor, Notch4; Receptors, Notch; Repressor Proteins; Ritonavir; Saquinavir; Vitamin E | 2008 |
Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir.
Topics: Animals; Chromatography, Liquid; HIV Protease Inhibitors; Male; Microsomes, Liver; Nelfinavir; Rats; Rats, Sprague-Dawley; Ritonavir; Saquinavir; Tandem Mass Spectrometry | 2008 |
A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4.
Topics: Animals; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Furans; Gene Expression; Gene Expression Regulation; HIV Protease Inhibitors; Humans; Intestine, Small; Ketoconazole; Liver; Male; Mice; Mice, Knockout; Mice, Transgenic; Microsomes, Liver; Models, Animal; Nelfinavir; Pregnane X Receptor; Pregnenolone Carbonitrile; Receptors, Steroid; Rifampin; Saquinavir; Sex Characteristics; Sulfonamides | 2008 |
Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors.
Topics: Animals; Cell Line, Tumor; HIV Protease Inhibitors; Humans; Leishmania; Leishmaniasis, Visceral; Lethal Dose 50; Macrophages; Nelfinavir; Ritonavir; Saquinavir | 2008 |
Beneficial effects of HIV peptidase inhibitors on Fonsecaea pedrosoi: promising compounds to arrest key fungal biological processes and virulence.
Topics: Amphotericin B; Animals; Antifungal Agents; Cell Adhesion; Cell Line; Chromoblastomycosis; Drug Synergism; HIV Protease Inhibitors; Humans; Macrophages; Nelfinavir; Saquinavir; Spores, Fungal; Virulence | 2008 |
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
Topics: Atazanavir Sulfate; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Kinetics; Lopinavir; Models, Molecular; Molecular Structure; Mutation; Nelfinavir; Oligopeptides; Pepsin A; Protein Binding; Protein Structure, Tertiary; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2009 |
Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Solid Phase Extraction; Sulfonamides | 2009 |
Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
Topics: Amino Acid Substitution; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Mutation, Missense; Nelfinavir; Portugal; Saquinavir; Selection, Genetic | 2009 |
HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone.
Topics: Adenosine Triphosphate; Animals; Atazanavir Sulfate; Benzoquinones; Cell Line; Cytosol; Glucose; Glutathione; HIV Protease Inhibitors; Insulin; Insulin Secretion; Insulin-Secreting Cells; Ion Channels; Mitochondria; Mitochondrial Proteins; Nelfinavir; Nigella sativa; Oligopeptides; Oxidative Stress; Plant Oils; Protective Agents; Pyridines; Rats; Reactive Oxygen Species; Saquinavir; Seeds; Superoxide Dismutase; Uncoupling Protein 2 | 2009 |
Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Cell Line; Cell-Free System; Cells; Dialysis; Dideoxynucleosides; Diphenylhexatriene; Dogs; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Fluorescent Dyes; HIV-1; Inhibitory Concentration 50; Mannitol; Micelles; Nelfinavir; Permeability; Poloxamer; Protease Inhibitors; Saquinavir; Surface-Active Agents; Temperature; Tetrahydroisoquinolines; Time Factors | 2009 |
A mass spectrometry based imaging method developed for the intracellular detection of HIV protease inhibitors.
Topics: Cell Line; Cyclotrons; Equipment Design; HIV Protease Inhibitors; Image Enhancement; Mass Spectrometry; Nelfinavir; Saquinavir; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Spectroscopy, Fourier Transform Infrared; Time Factors | 2009 |
Antiretroviral protease inhibitors potentiate chloroquine antimalarial activity in malaria parasites by regulating intracellular glutathione metabolism.
Topics: Animals; Anti-Retroviral Agents; Antimalarials; Chloroquine; Drug Resistance; Drug Synergism; Female; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; HIV Protease Inhibitors; Inhibitory Concentration 50; Malaria; Mice; Nelfinavir; Plasmodium chabaudi; Plasmodium falciparum; Ritonavir; Saquinavir | 2009 |
Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes.
Topics: Animals; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carbamates; Cells, Cultured; Fluoresceins; Furans; Hepatocytes; HIV Protease Inhibitors; Humans; Indinavir; Liver; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Nelfinavir; Rats; Rats, Wistar; Ritonavir; Saquinavir; Sulfonamides | 2010 |
Effects of HIV aspartyl-proteinase inhibitors on Leishmania sp.
Topics: Animals; Aspartic Acid Proteases; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; HIV Infections; HIV Protease Inhibitors; Humans; Leishmania infantum; Leishmania mexicana; Leishmaniasis; Macrophages; Mice; Monocytes; Nelfinavir; Saquinavir | 2010 |
Modulation of endocrine and transport functions in human trophoblasts by saquinavir and nelfinavir.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Caveolin 1; Chorionic Gonadotropin; Female; Giant Cells; HIV Protease Inhibitors; Humans; Maternal-Fetal Relations; Nelfinavir; Pregnancy; Saquinavir; Trophoblasts | 2010 |
HIV-1 protease mutations and protease inhibitor cross-resistance.
Topics: Atazanavir Sulfate; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Least-Squares Analysis; Lopinavir; Mutation; Nelfinavir; Oligopeptides; Organophosphates; Polymorphism, Genetic; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides | 2010 |
Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay.
Topics: Animals; Cell Separation; Clarithromycin; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enoxacin; Enzyme Inhibitors; Hepatocytes; Male; Microsomes, Liver; Midazolam; Nelfinavir; Rats; Rats, Sprague-Dawley; Saquinavir; Theophylline | 2010 |
The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Atazanavir Sulfate; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; HIV Protease Inhibitors; Humans; Immunoblotting; Immunohistochemistry; Lopinavir; Macrophages; Mice; Mice, SCID; Mice, Transgenic; Nelfinavir; Neurons; Oligopeptides; Pyridines; Ritonavir; Saquinavir | 2012 |
In vitro activity of antiretroviral drugs against Plasmodium falciparum.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antimalarials; Benzoxazines; Carbamates; Cyclopropanes; Darunavir; Furans; Lopinavir; Nelfinavir; Nevirapine; Plasmodium falciparum; Pyridines; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2011 |
Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.
Topics: Antiviral Agents; Atazanavir Sulfate; Carbamates; Carboxylic Ester Hydrolases; Drug Interactions; Furans; Humans; Kinetics; Models, Molecular; Nelfinavir; Oligopeptides; Protease Inhibitors; Pyridines; Quantitative Structure-Activity Relationship; Ritonavir; Saquinavir; Sulfonamides | 2012 |
Comparison of two drug safety signals in a pharmacovigilance data mining framework.
Topics: Anti-HIV Agents; Bayes Theorem; Data Mining; Databases, Factual; France; Humans; Myocardial Infarction; Nelfinavir; Pharmacovigilance; ROC Curve; Saquinavir; Sensitivity and Specificity | 2016 |
Nelfinavir is effective in inhibiting the multiplication and aspartic peptidase activity of Leishmania species, including strains obtained from HIV-positive patients.
Topics: Antiprotozoal Agents; Aspartic Acid Proteases; Colorimetry; Fluorometry; HIV Infections; Humans; Leishmania; Leishmaniasis; Microbial Viability; Nelfinavir; Oligopeptides; Saquinavir; Tetrazolium Salts; Thiazoles | 2013 |
Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.
Topics: Apoptosis; Cytotoxins; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Leukemic; HIV Protease Inhibitors; Humans; Leukemia, Myeloid, Acute; Lopinavir; Nelfinavir; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Ritonavir; Saquinavir; Signal Transduction; Tumor Cells, Cultured | 2014 |
Decoding the anti-Trypanosoma cruzi action of HIV peptidase inhibitors using epimastigotes as a model.
Topics: Animals; Anti-HIV Agents; Aspartic Acid Proteases; Carbamates; Furans; Host-Parasite Interactions; Indinavir; Insect Vectors; Lopinavir; Microscopy, Electron, Transmission; Nelfinavir; Protease Inhibitors; Ritonavir; Saquinavir; Sulfonamides; Trypanocidal Agents; Trypanosoma cruzi | 2014 |
Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
Topics: Crystallography, X-Ray; Drug Resistance, Viral; Fluorometry; HIV Protease; HIV Protease Inhibitors; HIV-1; Models, Molecular; Mutation; Nelfinavir; Protein Folding; Saquinavir; Structure-Activity Relationship | 2015 |
Docking simulation between HIV peptidase inhibitors and Trypanosoma cruzi aspartyl peptidase.
Topics: Anti-HIV Agents; Aspartic Acid Proteases; Atazanavir Sulfate; Crystallography, X-Ray; Databases, Protein; Drug Repositioning; HIV; Molecular Docking Simulation; Nelfinavir; Peptide Hydrolases; Protease Inhibitors; Protein Conformation; Saccharomyces cerevisiae Proteins; Saquinavir; Trypanosoma cruzi | 2018 |
Systems Pharmacology Identifies an Arterial Wall Regulatory Gene Network Mediating Coronary Artery Disease Side Effects of Antiretroviral Therapy.
Topics: Anti-Retroviral Agents; Arteries; Atherosclerosis; Cholesterol Esters; Coronary Artery Disease; Databases, Nucleic Acid; DNA-Binding Proteins; Foam Cells; Gene Regulatory Networks; HIV Infections; Humans; Macrophages; Nelfinavir; Ritonavir; Saquinavir; THP-1 Cells | 2019 |
Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation.
Topics: Betacoronavirus; Binding Sites; Biophysical Phenomena; Catalytic Domain; Computational Biology; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; Cysteine Endopeptidases; Darunavir; Drug Repositioning; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Molecular Dynamics Simulation; Nelfinavir; Pandemics; Pneumonia, Viral; Ritonavir; Saquinavir; SARS-CoV-2; Viral Nonstructural Proteins | 2020 |